Chroman 1
(Synonyms: (3S)-N-[2-[2-(二甲基氨基)乙氧基]-4-(1H-吡唑-4-基)苯基]-3,4-二氢-6-甲氧基-2H-1-苯并吡喃-3-甲酰胺,ROCK-II inhibitor) 目录号 : GC16097A ROCK2 inhibitor
Cas No.:1273579-40-0
Sample solution is provided at 25 µL, 10mM.
Chroman 1 is a highly potent ROCK-II inhibitor. ROCK is a member of the AGC kinase family of serine/threonine kinases that is comprised of two highly homologous isoforms, which are ROCK-I and ROCK-II.. As one of the downstream effectors of RhoA, ROCK regulates stress fiber formation and actin cytoskeletal organization via phosphorylation of myosin light chain. Currently, there is plenty of interest in the inhibition of Rho kinase (ROCK) to treat various diseases.
In vitro: Chroman 1 was found to be a sub-nanomolar ROCK-II inhibitor with excellent to moderate selectivity over related kinases studied as a preliminary assessment, such as AKT1, protein kinase A (PKA), and the highly homologous Cdc42-binding kinase. In addition, Chroman 1 also showed good in-vitro activity in the functional cell-based myosin light chain bis-phosphorylation assay [1].
In vivo: Pharmacokinetic evaluation in rats showed that Chroman 1 had moderately improved oral bioavailability (27–35%) relative to its lead compounds, which were benzodioxane and chroman. In addition, Chroman 1 also displayed an unique intriguing pharmacokinetic profile, which was with high systemic exposure through oral delivery [1].
Clinical trial: So far, there is no clinical study reported.
References:
[1] Chen YT,Bannister TD,Weiser A,Griffin E,Lin L,Ruiz C,Cameron MD,Schürer S,Duckett D,Schrter T,LoGrasso P,Feng Y. Chroman-3-amides as potent Rho kinase inhibitors. Bioorg Med Chem Lett.2008 Dec 15;18(24):6406-9.
Kinase experiment: |
Assays are performed using the HTRF KinEASE STK S2 kit. A 5 μL mixture of 1 μM STK2 substrate and 20 μM ATP in STK-buffer is added to the wells. Inhibitor (including Chroman 1, 20 nL) at various concentrations is then dispensed. Reaction is started by addition of 0.5 nM ROCK-II in STK-buffer (5 μL). After 4 h at room temperture (rt), the reaction is stopped by addition of 10 μL mixture of 1× STK antibody-Cryptate in detection buffer and 62.5 nM Sa-XL in detection buffer. After 1 h at rt, the plates are read on the Viewlux in HTRF mode[1]. |
References: [1]. Yen Ting Chen, et al. Asymmetric synthesis of potent chroman-based Rho kinase (ROCK-II) inhibitors. Med.Chem.Commun., 2011, 2, 73-75. |
Cas No. | 1273579-40-0 | SDF | |
别名 | (3S)-N-[2-[2-(二甲基氨基)乙氧基]-4-(1H-吡唑-4-基)苯基]-3,4-二氢-6-甲氧基-2H-1-苯并吡喃-3-甲酰胺,ROCK-II inhibitor | ||
化学名 | (3S)-N-[2-[2-(dimethylamino)ethoxy]-4-(1H-pyrazol-4-yl)phenyl]-6-methoxy-3,4-dihydro-2H-chromene-3-carboxamide | ||
Canonical SMILES | CN(C)CCOC1=C(C=CC(=C1)C2=CNN=C2)NC(=O)C3CC4=C(C=CC(=C4)OC)OC3 | ||
分子式 | C24H28N4O4 | 分子量 | 436.5 |
溶解度 | DMSO: ≥ 40 mg/mL | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.291 mL | 11.4548 mL | 22.9095 mL |
5 mM | 0.4582 mL | 2.291 mL | 4.5819 mL |
10 mM | 0.2291 mL | 1.1455 mL | 2.291 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet